Company intelligence / Profile preview

Bardy Diagnostics

Bellevue, Washington, United Statesbardydx.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

The CAM patch has been clinically validated to provide superior clarity in P-wave signal capture compared to traditional Holter monitors. It enables up to 14 days of continuous ambulatory ECG recording with high diagnostic yield for arrhythmia detection. The device’s design improves patient compliance and comfort. AI-enabled automatic screening technology for atrial fibrillation has also been validated as part of their R&D pipeline.

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health solution
Industry: Physiological Monitoring

Partnerships

Integration with hospital systems via BDxConnect portal

Beyond the preview

Go deeper on Bardy Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bardy Diagnostics.

Explore the full profile